← All trials
NCT05465889
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2019
- Primary completion
- Jan 9, 2020
- Completion date
- Mar 15, 2020
- First posted
- Jul 20, 2022
- Last posted
- Jul 26, 2022
- Enrollment
- 348
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Changhai HospitalLead sponsor
- Peking UniversityCollaborator
- Changhai HospitalReponsible party - principal investigator
- Hebei Medical UniversityCollaborator
- Henan Provincal People's HospitalCollaborator
- Shandong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Nanchang UniversityCollaborator
- Xiamen UniversityCollaborator
- Changhai HospitalSponsor investigator
- Jilin UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.